Add BrightSurf on Google Email

Moffitt study shows promise for new treatment in patients with leptomeningeal disease

A phase 1B clinical trial found that combining avelumab with whole brain radiotherapy provides a safe and effective treatment option for patients with leptomeningeal disease, with 67% of patients alive three months after treatment. The study also showed an adaptive immune response to treatment, reducing levels of regulatory T cells.

SourceH. Lee Moffitt Cancer Center & Research Institute·JournalNeuro-Oncology·TypeRandomized controlled/clinical trial·DateSep 30, 2025

Targeting glypican-3 for liver cancer therapy

Glypican-3 is a key driver of hepatocellular carcinoma progression, facilitating metastasis and tumor microenvironment remodeling. Immunotherapy targeting GPC3 has shown preliminary safety and antitumor activity in clinical trials, with ongoing research focusing on optimized patient selection and disease monitoring.

SourceXia & He Publishing Inc.·JournalJournal of Clinical and Translational Hepatology·DateSep 30, 2025

Chinese Medical Journal review highlights neoadjuvant therapy’s promise in advanced colon cancer treatment

Recent clinical trials demonstrate the potential benefits of neoadjuvant chemotherapy and immunotherapy in improving tumor response and surgical success for patients with locally advanced colon cancer. The approach also reduces the risk of recurrence and metastasis, increasing survival outcomes and decreasing cancer-related complications.

SourceChinese Medical Journals Publishing House Co., Ltd.·JournalChinese Medical Journal·TypeLiterature review·DateSep 19, 2025

Possible breakthrough in the development of effective biomaterials

A research team led by Professor Shikha Dhiman has discovered that the speed of receptors in model cell membranes plays a crucial role in binding to biomaterials. When ligands move at similar speeds, they can bind to receptors, enabling effective tissue engineering and medical applications.

SourceJohannes Gutenberg Universitaet Mainz·JournalProceedings of the National Academy of Sciences·TypeObservational study·DateSep 19, 2025

Research spotlight: Combination therapy shows promise for overcoming treatment resistance in glioblastoma

Researchers identified Wnt7b as a determinant of resistance to immune checkpoint blockers in glioblastoma and developed a combination therapy with WNT974 that sensitizes GBM to anti-PD1 therapy, improving anti-tumor immunity. This approach offers a promising new therapeutic avenue for glioblastoma patients.

SourceMassachusetts General Hospital·JournalProceedings of the National Academy of Sciences·TypeExperimental study·DateSep 18, 2025

Bioengineered lymph nodes offer window into human immunity

Researchers at NUS have developed a bioengineering approach to keep human lymph node tissue alive and functioning outside the body for several days. The method involves embedding thin slices of lymph node tissue in a soft gel that mimics the body's natural environment, allowing for detailed studies of immune cell behavior.

SourceNational University of Singapore College of Design and Engineering·JournalTrends in Biotechnology·TypeExperimental study·DateSep 10, 2025

Immune cell therapy for advanced head and neck cancer helps stabilize disease

A phase 2 clinical trial found that autologous tumor-infiltrating lymphocyte (TIL) cell therapy helped stabilize metastatic head and neck squamous cell carcinoma (HNSCC) in some patients. The median response duration was 7.6 months, with cancer stabilization occurring in 64% of patients.

SourceUniversity of North Carolina Health Care·JournalJournal for ImmunoTherapy of Cancer·TypeRandomized controlled/clinical trial·DateAug 28, 2025

Moffitt study uncovers new mechanism of immunotherapy resistance

A new study by Moffitt Cancer Center researchers has found that cancer-induced nerve injury weakens the effectiveness of anti-PD-1 immunotherapy. The study shows that cancer cells infiltrate and damage tumor-associated nerves, triggering an inflammatory response that ultimately suppresses the immune system's ability to fight cancer.

SourceH. Lee Moffitt Cancer Center & Research Institute·JournalNature·TypeObservational study·DateAug 21, 2025

Moffitt study finds promising new combo therapy for drug-resistant melanoma

A new study from Moffitt Cancer Center found that a combination of immune-targeting drugs, including TIM-3, was effective in shrinking tumors in lab models of treatment-resistant melanoma. The triplet therapy also restored immune function and led to complete tumor regressions in some cases.

SourceH. Lee Moffitt Cancer Center & Research Institute·JournalJournal for ImmunoTherapy of Cancer·TypeObservational study·DateAug 18, 2025

Application of spatial and single-cell omics in tumor immunotherapy biomarkers

Emerging technologies like spatial and single-cell omics improve our understanding of tumor biology and facilitate personalized cancer immunotherapies. These approaches enable researchers to identify novel biomarkers that predict therapeutic responses and monitor disease progression in real-time, ultimately improving patient outcomes.

SourceShanghai Jiao Tong University Journal Center·JournalLabMed Discovery·TypeObservational study·DateAug 3, 2025

Study identifies genes that can predict response to immunotherapy in melanoma patients

A recent study identified four genes associated with treatment resistance to immunotherapy in melanoma patients. The genes, CD24, NFIL3, FN1, and KLRK1, were found to be linked to mechanisms of immune evasion and suppression of the inflammatory response. Patients with high expression of these genes had significantly lower overall survi...

SourceFundação de Amparo à Pesquisa do Estado de São Paulo·JournalJournal of Molecular Medicine·DateJul 30, 2025

Research alert: Synergistic treatment approach supercharges cancer immunotherapy

Researchers at UC San Diego School of Medicine have developed a novel approach to enhance the effectiveness of immunotherapy treatments for head and neck squamous cell carcinomas (HNSCC). Delivering radiation therapy that preserves tumor-draining lymph nodes followed by immunotherapy resulted in a complete and durable tumor response in...

SourceUniversity of California - San Diego·JournalNature Communications·DateJul 28, 2025

An “innate immunity + local immune activation” combination strategy: Systemic IFN-I and topical TLR7/8-based antitumor immunotherapy strategy —a perspective from Bo Xiao and Chenghui Wang's group at University of Electronic Science and Technology of

Researchers propose a synergistic combination strategy using systemic type I interferons (IFN-I) and local TLR7/8 agonists to enhance dendritic cell activation and inhibit metastatic tumors. This approach enhances early innate immune control and later induces CD8+ T cell responses.

SourceResearch·JournalResearch·TypeNews article·DateJul 24, 2025

Korea University researchers reveal revealing how WEE1 drives cancer resistance to immunotherapy

Researchers from Korea University have discovered that the protein WEE1 can paradoxically drive immune resistance in cancer cells when located in the cytoplasm. This study suggests that targeting WEE1 with an inhibitor, such as adavosertib, may sensitize tumors to immunotherapy and reinvigorate antitumor immunity.

SourceKorea University College of Medicine·JournalCancer Immunology Research·TypeExperimental study·DateJul 15, 2025

Most patients with advanced melanoma who received pre-surgical immunotherapy remain alive and disease free four years later

A Phase II study found that 87% of patients with stage III melanoma remained alive and disease-free four years after treatment with nivolumab and relatlimab. Researchers identified unique biomarkers associated with better outcomes, including high TIGIT levels and low B7-H3 levels.

SourceUniversity of Texas M. D. Anderson Cancer Center·JournalJournal of Clinical Oncology·DateJul 10, 2025

Real-world data shows teclistamab can benefit many multiple myeloma patients who would have been ineligible for pivotal trial

A retrospective study found teclistamab-cqyv to be effective in patients with high-risk, heavily pretreated multiple myeloma who would have been ineligible for the MajesTEC-1 trial. The bispecific antibody reduced disease burden by at least half in 53% of evaluable patients, and 45% achieved a 'very good partial response'. Despite a hi...

SourceAmerican Association for Cancer Research·JournalBlood Cancer Discovery·DateJul 9, 2025

A new cell therapy for leukaemia shows high efficacy and safety in the laboratory

A new dual CAR-T cell therapy has been developed to target T-ALL, showing high efficacy and safety. The treatment targets two antigens simultaneously, making it more effective than previous therapies. Experimental results demonstrate its ability to control the disease in both laboratory and animal models, with an excellent safety profile.

SourceJosep Carreras Leukaemia Research Institute·JournalJournal of Hematology & Oncology·TypeExperimental study·DateJul 7, 2025

Exciting progress in ferroptosis-based nanomedicine for bladder cancer

Researchers develop self-assembling nanoparticles that induce ferroptosis in bladder cancer cells while reprogramming the tumor immune microenvironment, boosting anti-tumor activity. The nanomedicine has dual functions as a multifaceted approach to overcome treatment resistance and is Clinically translatable.

SourceResearch·JournalResearch·TypeExperimental study·DateJul 6, 2025

New insights into natural killer cell brakes point to more effective combination cancer therapies

Researchers have discovered that blocking NK cell checkpoints could significantly enhance cancer immunotherapy, providing new avenues for treating solid tumors and blood cancers. Emerging precision approaches using gene editing and engineered cell therapies promise specific recognition of cancer cells with potentially fewer side effects.

SourceResearch·JournalResearch·TypeNews article·DateJul 1, 2025

Neopred: A dual-phase CT AI tool for preoperative prediction of pathological response in NSCLC

A new dual-phase CT AI tool, NeoPred, combines pre-treatment and pre-surgery scans with clinical data to predict major pathological response in NSCLC patients. The model achieved high accuracy rates, including AUCs of 0.772-0.787, outperforming surgeons and improving diagnostic accuracy.

SourceNational Center for Respiratory Medicine·JournalJournal for ImmunoTherapy of Cancer·TypeComputational simulation/modeling·DateJun 26, 2025

Official BRACELET-1 trial results indicate that adding the oncolytic virus immunotherapy pelareorep to paclitaxel chemotherapy warrants further investigation in HR+ HER2- metastatic breast cancer

The BRACELET-1 trial demonstrated a 20% objective response rate and 12.1-month progression-free survival for patients with unresectable HR+ HER2- tumors, suggesting that adding pelareorep to paclitaxel chemotherapy warrants further investigation in metastatic breast cancer.

SourcePrECOG, LLC·JournalClinical Cancer Research·TypeRandomized controlled/clinical trial·DateJun 24, 2025

Perioperative toripalimab and chemotherapy in resectable non-small cell lung cancer: Another weapon in the armamentarium

The addition of perioperative toripalimab to platinum-based chemotherapy has demonstrated significant improvements in disease-related outcomes, including event-free survival and major pathologic response rates. However, this is associated with a small increase in grade 3–5 toxicities and immune-related adverse events.

SourceNational Center for Respiratory Medicine·JournalJournal of Thoracic Disease·TypeCommentary/editorial·DateJun 19, 2025